ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,609,363 | +673.8% | 144,079 | +1382.4% | 0.00% | – |
Q2 2023 | $207,987 | -74.5% | 9,719 | -51.9% | 0.00% | – |
Q1 2023 | $816,322 | +245.9% | 20,186 | +539.4% | 0.00% | – |
Q4 2021 | $236,000 | -62.6% | 3,157 | -71.6% | 0.00% | – |
Q3 2021 | $631,000 | +58.1% | 11,100 | +22.5% | 0.00% | – |
Q2 2021 | $399,000 | +99.5% | 9,060 | +90.6% | 0.00% | – |
Q4 2020 | $200,000 | -24.2% | 4,753 | -17.6% | 0.00% | – |
Q3 2020 | $264,000 | +26.9% | 5,767 | +39.5% | 0.00% | – |
Q2 2020 | $208,000 | -30.2% | 4,135 | -14.3% | 0.00% | – |
Q4 2019 | $298,000 | -15.6% | 4,826 | -17.9% | 0.00% | -100.0% |
Q3 2019 | $353,000 | +69.7% | 5,880 | +138.8% | 0.00% | – |
Q2 2019 | $208,000 | -45.3% | 2,462 | -54.1% | 0.00% | -100.0% |
Q4 2018 | $380,000 | -63.6% | 5,364 | -40.4% | 0.00% | -50.0% |
Q2 2018 | $1,043,000 | +340.1% | 9,000 | +50.5% | 0.00% | 0.0% |
Q3 2014 | $237,000 | -49.3% | 5,981 | -44.9% | 0.00% | -66.7% |
Q2 2014 | $467,000 | – | 10,851 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |